Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications
CA 2697207 A1 · Owner: Pgxhealth Holding, Inc. · Inventors: Eichelbaum, Michel; Hoffmeyer, Sven; Roots, Ivar
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Described are general means and methods of diagnosing and treating the phenotypic , spectrum as well as the overlapping clinical characteristics with several forms of , inherited abnormal expression and/or function of the Multi Drug Resistance-1 (MDR--1) gene. In particular, polynucleotides of molecular variant MDR-1 genes which, for , example, are associated with unsufficient and/or altered uptake of drugs by a target , cell, and vectors comprising such polynucleotides are provided. Furthermore host , cells comprising such polynucleotides or vectors and their use for the production of , variant MDR-1 proteins are described. In addition variant MDR-1 proteins and , antibodies …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 28, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 28, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 28, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.